Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY: GSK )

34.12 +0.09 (+0.26%)
Official Closing Price Updated: 7:00 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
35 36 Next >
Intel Voices Plans To Restructure Manufacturing Business, Bumble's BFF App, Spirit AeroSystems To Stop Work At Kansas Plant Amid Workers Strike: Today's Top Stories
Reuters 
Via Benzinga
RSV Vaccines from Pfizer and GSK Gain CDC Advisory Committee's Favor for Older Adults
The US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices voted in favor of recommending the use of RSV vaccines from Pfizer Inc (NYSE: PFE) and GSK... 
Via Benzinga
7 Healthcare Stocks to Make You the Millionaire Next Door
For investors who want to greatly increase their wealth in the long term, these are the best healthcare stocks to buy. 
Via InvestorPlace
US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend AREXVY for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making
From GSK plc
Via Business Wire
Peering Into GSK's Recent Short Interest
Via Benzinga
Pfizer's Elderly Vaccine Efficacy Drops Slightly After 18 Months, New Clinical Trials Reveal - CDC Advisory Panel Set To Vote Today On Recommended Use Of RSV Shots
Pfizer Inc's (NYSE: PFE) vaccine for elderly 60 and above was slightly less effective after 18 months, according to the company's clinical trial  
Via Benzinga
GSK's Recently Approved Vaccine Offers Long-Term Protection Against RSV in Older Adults, New Data Reveals
GSK plc (NYSE: GSK) announced  
Via Benzinga
GSK shares positive data for AREXVY, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons
From GSK plc
Via Business Wire
GSK and Lifetime® Release Short Film Featuring Soleil Moon Frye and Melissa Joan Hart Urging Parents to “Ask2BSure” about Meningitis B
From GSK plc
Via Business Wire
Sanofi Stock Is Trading Higher Today - Here's Why
Sanofi SA (NASDAQ: SNY) announced that the tribunal dismissed Boehringer Ingelheim's indemnification claim against Sanofi in an International Chamber of Commerce dispute in cancer lawsuits linked to... 
Via Benzinga
3 Undervalued Consumer Stocks to Buy in June
These undervalued consumer stocks to buy could attract investor attention as possible hedges against inflation and a recession. 
Via InvestorPlace
3 Gene Testing Stocks to Buy Before They Take Off
The future of gene testing is bright thanks to an aging population. Here are three companies leading the industry. 
Via InvestorPlace
UK Gives Nod To Roomba Maker IRobot-Amazon Deal, Micron Plans To Invest In China Despite Restrictions, Baidu Secures Regulatory Nod for Self-Driving Taxi: Today's Top Stories
Benzinga 
Via Benzinga
2 Top Healthcare Stocks to Buy Right Now
The demand for healthcare sector goods and services is both predictable and growing. 
Via The Motley Fool
Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M
Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that  
Via Benzinga
FDA Pushes Review Time For GSK's Blood Cancer Therapy Added Via Sierra Oncology Acquisition
The FDA has extended the review period for GSK plc's (NYSE: 
Via Benzinga
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action
FN Media Group Presents USA News Group News Commentary Vancouver, BC – June 8, 2023 – USA News Group – By utilizing newly developed novel mechanisms, biotech researchers and scientists are making... 
Via FinancialNewsMedia
ChatGPT's Parent Has No IPO Plans, CNN CEO Chris Licht Out, Kim Kardashian's Bid To Dismiss EthereumMax Lawsuit Rejected: Today's Top Stories
Benzinga Cable Giant CNN Chairman, CEO Chris Licht Moves Out 
Via Benzinga
GSK's Arexvy Gets the Green Light in Europe: First-Ever RSV Vaccine in Europe for Older Adults
The European Commission has approved GSK plc's (NYSE:  
Via Benzinga
June 2023 Stock Considerations
With a new trading month already in full swing it is time, once again, to highlight some of my potential stock purchases. 
Via Talk Markets
SEC Accuses Binance & Coinbase Of Acting As Unregistered Broker, Binance Takes Biggest Hit As $300M In Crypto Positions Liquidated In 24 Hours, JPMorgan Clarifies CEO Jamie Dimon Not Running For Presidency: Today's Top Stories
Benzinga 
Via Benzinga
FDA Prioritizes GSK's Breakthrough Drug Jemperli for Endometrial Cancer Treatment, a First in Decades
Via Benzinga
GSK Announces the COiMMUNITY Initiative to Help Achieve Higher Adult Vaccination Rates in the US
From GSK plc
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
WHO Recommends New COVID Booster Shots To Target XBB Variants, Despite Slower Uptake
An advisory group for the World Health Organization said the current crop of shots should be updated to target the currently dominant XBB strains for the 
Via Benzinga
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
From BELLUS Health Inc.
Via Business Wire
Could Latecomer Moderna Match Big Pharma Rivals in RSV?
RSV is a key part of Moderna's respiratory vaccine business. 
Via The Motley Fool
A Bitter Pill to Swallow: Teva's $235M Challenge to GSK Dismissed by Supreme Court
The U.S. 
Via Benzinga
3 Personalized Medicine Stocks to Buy for Long-Time Returns
Personalized medicine is the future of medicine. Here are three personalized medicine stocks to invest in so you don't miss out. 
Via InvestorPlace
GSK's Meningitis Vaccine Candidate: Crushing Clinical Trials or Just Playing Catch-up with Bexsero and Menveo?
GSK plc (NYSE: GSK) presented preliminary results from the phase 3 trial of imm 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.